A Phase I Study of LuoXin Innovate (LXI-15028) in Healthy Chinese Subjects to Evaluate the Pharmacokinetics, Safety and Tolerability.
Clinical trial NCT03458650 · COMPLETED
Trial details
- NCT number
- NCT03458650
- Sponsor
- Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-03-19
- Primary completion
- 2018-04-23
- Enrollment
- 38
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.